PALM BEACH, Fla., Feb. 14, 2024 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - Recent reports project that the anal cancer market will continue its recent growth through 2030. An article on the MD Anderson website. It said: "More than 8,000 people in the U.S. are diagnosed with anal cancer each year. Due to higher rates of the human papilloma virus, a key risk factor, it affects women more than men. If found early, the disease can be successfully treated. Several types of tumors may be found in the an ...

NEW YORK--(BUSINESS WIRE)--VantAI, a company focused on generative AI-enabled drug discovery, and Bristol Myers Squibb (NYSE: BMY), a leading pharmaceutical company, have entered into a strategic collaboration to discover new molecular glues for therapeutic targets of interest. The partnership leverages VantAI's geometric deep learning capabilities with Bristol Myers Squibb’s expertise in targeted protein degradation to discover and develop new small molecule therapeutics. The collaboration will focus on ...

The fourth-quarter results of the healthcare sector have been unimpressive, with earnings of companies that have reported so far down 17.7% despite 7% revenue growth. The earnings beat ratio of 79.4% and revenue beat ratio of 85.3% are assuring, though. Combining the actual results with the estimates for the still-to-report companies, the total earnings of the sector are expected to decline 18.2% despite revenue growth of 5.3%.However, many industry bigwigs reported solid results, with some beating on earni ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ___________________________ FORM 10-K ___________________________ ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ______ to _______ Commission File Number 001-01136 ___________________________ BRISTOL-MYERS SQUIBB COMPANY (Exact nam ...

PRINCETON, N.J. & SAN DIEGO--(BUSINESS WIRE)--Bristol Myers Squibb (NYSE: BMY) and RayzeBio, Inc. (Nasdaq: RYZB) today announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, or HSR Act, in connection with Bristol Myers Squibb’s previously announced tender offer to acquire all of the outstanding shares of RayzeBio common stock for a purchase price of $62.50 per share in cash, or approximately $4.1 billion. The expiration of the waiting period occurred a ...

Drugmakers grilled on the cost of prescription drugs on Capitol Hill Thursday sought to deflect the criticism onto drug-market middlemen who they said are pushing list prices for medications higher. The chief executives of Johnson & Johnson JNJ, -0.96%, Merck & Co. MRK, -0.63% and Bristol Myers Squibb Co. BMY, -0.05% were faced with sharp questioning from Sen. Bernie Sanders, the Vermont independent, and other members of the Senate Health, Education, Labor and Pensions Committee demanding to know why U.S. p ...

Jazz Pharmaceuticals plc (JAZZ) announced that it has entered into a definitive agreement with U.K.-based biotech Redx Pharma to acquire global rights to the latter’s preclinical KRAS (Kirsten rat sarcoma virus) inhibitor program.Per the agreement, Jazz will make an upfront payment of $10 million to Redx to gain all rights, patents and interest related to its proprietary KRAS inhibitor program, including its G12D selective and pan-KRAS molecules.Further, Redx is entitled to receive up to $870 million in the ...

ToplineChief executives from three major pharmaceutical companies will testify before a Senate committee on Thursday, following a back-and-forth with Sen. Bernie Sanders (I-Vt.), who has accused the firms of overcharging Americans for prescription drugs.Johnson & Johnson and Merck have accused Sen. Bernie Sanders of unjustly targeting the companies.getty Key FactsJohnson & Johnson CEO Joaquin Duato, Merck CEO Robert Davis and Bristol Myers Squibb CEO Chris Boerner will testify before the Senate Committee on ...

Sen. Bernie Sanders, left, appears at a news conference with Sen. Ed Markey on issuing subpoenas for pharmaceutical company CEOs to testify regarding drug prices, in the Capitol, Jan. 25, 2024.Senators will question the CEOs of Johnson & Johnson, Merck and Bristol Myers Squibb on U.S. drug prices at a hearing Thursday, as lawmakers on both sides of the aisle work to rein in high health-care costs for Americans. The push to cut drug prices is one of those rare hot-button issues that unites the two major poli ...

Lawmakers seeking to hold drugmakers accountable for high prescription-drug costs are focusing on some prices that shed little light on the problem, drug-pricing experts say. The CEOs of Merck & Co. Inc. MRK, +0.49%, Johnson & Johnson JNJ, -0.11% and Bristol Myers Squibb Co. BMY, -1.50% are set to appear before the Senate Health, Education, Labor and Pensions Committee on Thursday for a hearing examining why U.S. prescription-drug prices are far higher than those in other countries. Merck CEO Robert Davis a ...